Abstract OBJECTIVE: To study the prognostic significance of CD47 in a NOD/SCID mouse model of acute myeloid leukemia (AML) and the best strategy for targeted therapy for this disease. METHODS: CD34+CD38- leukemia stem cells (LSCs) were separated and transplanted into NOD/SCID mice to establish a mouse model of acute monocytic leukemia (AMoL). Anti-human CD47 antibody, alone or combined with cytosine arabinoside (Ara-C), was used to treat the mice with AMoL for 7-14 days, and therapeutic efficacy was assessed. LSCs were cultured together with mouse macrophages in culture medium containing anti-CD47 or anti-CD45 monoclonal antibody for 2 hours, to observe the phagocytic ability of macrophages to LSCs. RESULTS: CD34+CD38- LSCs existed among THP-1 cells, with a content of about (0.12±0.06)%, and a mouse model of AML was successfully established after the purified CD34+CD38- LSCs (97.0%±1.7%) were transplanted into NOD/SCID mice. The in vivo experiment showed that mice with AMoL had the most significant decrease in CD33+CD45+ leukemia cells in peripheral blood and bone marrow and survived the longest after being treated with Ara-C (7 days) plus anti-CD47 monoclonal antibody (14 days) (P<0.01). After 2 hours of in vitro culture, the phagocytic index in the culture medium containing anti-CD47 monoclonal antibody was significantly higher than in the culture medium containing anti-CD45 monoclonal antibody (76.9%±12.2% vs 7.60%±2.4%; P<0.05). CONCLUSIONS: High expression of CD47 is an adverse prognostic factor in AML. Combination therapy with anti-CD47 monoclonal antibody and Ara-C can effectively eliminate leukemia cells and LSCs, demonstrating great clinical significance in curing AML.
WANG Ying-Chao,FENG Lei,YIN Chu-Yun et al. Effectiveness of Anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia[J]. CJCP, 2013, 15(7): 577-582.
WANG Ying-Chao,FENG Lei,YIN Chu-Yun et al. Effectiveness of Anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia[J]. CJCP, 2013, 15(7): 577-582.
［3］Smith ML, Hills RK, Grimwade D. Independent prognostic variables in acute myeloid leukaemia［J］. Blood Rev, 2011, 25(1):39-51.
［4］Zhai XW, Cheng FW, Lee V, Leung WK, Ng MH, Tsang KS, et al. Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children［J］. Pediatr Hematol Oncol, 2011, 28(4): 269-278.
［5］Guzman ML, Rossi RM, Kamisehky L, Li X, Peterson DR, Howard DS, et al. The sesquiterpenel aetone Parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells［J］. Blood, 2005, 105(11): 4163-4169.
［6］Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia［J］. Proc Natl Acad Sci USA, 2007,104(26): 11008-11013.
［7］Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI, et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells［J］. Nat Immunol, 2007, 8(12): 1313-1323.
［9］Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia［J］. Cancer Res, 2011, 71(4): 1374-1384.
［10］Coebergh JW, Reedijk AM, deVries E, Martos C, Jakab Z, Steliarova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project［J］. Eur J Cancer, 2006, 42(13): 2019-2036.
［11］Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance［J］. Nat Rev Cancer, 2005, 5(4): 275-284.
［12］Felipe Rico J, Hassane DC, Guzman ML. Acute myelogenous leukemia stem cells: From Bench to Bedside［J］. Cancer Lett, 2012［Epub ahead of print］.
［13］Wang Y, Schulte BA, LaRue AC, Ogawa M, Zhou D. Total body irradiation selectively induces murine hematopoietic stem cell senescence［J］. Blood, 2006, 107 (1): 358-366.
［14］Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy resistant human AML stem cells home to and engraft within the bone marrow endosteal region［J］. Nat Biotechnol, 2007, 25(11): 1315-1321.
［15］Burger JA, Peled A. CXCR4 antagonists: Targeting the microe-vironment in leukemia and other cancers［J］. Leukemia, 2009, 23(1): 43-52.
［16］Barclay AN, Brown MH. The SIRP family of receptors and immune regulation［J］. Nat Rev Immunol, 2006, 6(6): 457-464.
［17］Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis［J］. Cell, 2009, 138(2): 271-285.
［18］Willingham SB, Volkmer JP, Gentles AJ, SahooD, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors［J］. Proc Natl Acad Sci USA, 2012, 109(17): 6662-6667.
［19］Blazar BR, Lindberg FP, Ingulli E, Panoskaltsis-Mortari A, Oldenborg PA, Lizuka K, et al. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counter receptors is required to prevent the clearance of donor lymphohematopoietic cells［J］. J Exp Med, 2001, 194(4): 541-549.
［21］Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells［J］. Leukemia, 2012, 26(12):2538-2545.
［22］Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma［J］. Cell, 2010, 142(5): 699-713.
［23］Kikuchi Y, Uno S, Yoshimura Y, Otabe K, Lida S, Oheda M, et al. A bivalent single chain Fv fragment against CD47 induces apoptosis for leukemic cells［J］. Bio chem Biophys Res Commun, 2004, 315(4): 912-918.
［24］Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KDJ, et al. CD47 is an adverse prognostic factor and therapeutic anti body target on human acute myeloid leukemia stem cells［J］. Cell, 2009,138(2): 286-299.
